Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ideaya Biosciences Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.ideayabio.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Yujiro S. Hata, MBA
Number Of Employees: 131
Enterprise Value: $1,441,978,373
PE Ratio: -5.17
Exchange/Ticker 1: NASDAQ:IDYA
Exchange/Ticker 2: N/A
Latest Market Cap: $1,492,512,640
BioCentury | Feb 11, 2025
Management Tracks
Ideaya hires J.P. Morgan veteran Joshua Bleharski as CFO
Plus: Winselow Tucker named president of Lilly India, and updates from Santhera, Aurion and Oncolytics
BioCentury | Aug 6, 2024
Deals
Deals Report: Bispecific space continues to foster partnerships
Plus: Otsuka in $800M takeout of Jnana, BioNTech dropping Genmab’s acasunlimab
BioCentury | Jul 13, 2024
Finance
Public Equity Report: Ideaya, Cartesian raise catalyst-driven deals
Plus: Artiva takes second look at IPO, Moderna gets $176M BARDA award
BioCentury | Jul 10, 2024
Product Development
Clinical Report: uniQure’s Huntington readout, Ideaya’s MAT2A data drive shares up
Plus: A HilleVax vaccine disappoints, and another TIGIT miss for Genentech
BioCentury | May 6, 2024
Product Development
Tale of two WRN inhibitors: a covalent and a non-covalent molecule enter the clinic
As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms
BioCentury | May 2, 2024
Finance
Venture report: Rounds for psychedelic play Reunion, cancer company Delphia
Plus: Syndicate backs BridgeBio’s cancer spinout, AbCellera teams with investors to form asset-focused newcos, and more
BioCentury | Nov 7, 2023
Data Byte
October marks year’s third-biggest month for biotech follow-ons
The group’s median market cap performance was positive
BioCentury | Oct 25, 2023
Management Tracks
CFO Joanne Bryce to depart Disc
Plus: Jeff Albers joins Scorpion as strategic adviser, and updates from Mironid, 1859, mbiomics and Tevogen
BioCentury | May 5, 2023
Data Byte
Two big deals led April’s follow-ons
11 biopharmas raised $968M in April. A fast start to May could rekindle momentum
BioCentury | Apr 25, 2023
Product Development
April 24 Quick Takes: Ideaya gains on uveal melanoma data
Plus: Foghorn pauses targeted degrader study and updates from bluebird, Lilly, MaaT, Biosion
Items per page:
1 - 10 of 49